ZA958314B - 5-Ht1f mediated inhibition of neurogenic meningeal extra-vasation a method for the treatment of migraine - Google Patents
5-Ht1f mediated inhibition of neurogenic meningeal extra-vasation a method for the treatment of migraineInfo
- Publication number
- ZA958314B ZA958314B ZA958314A ZA958314A ZA958314B ZA 958314 B ZA958314 B ZA 958314B ZA 958314 A ZA958314 A ZA 958314A ZA 958314 A ZA958314 A ZA 958314A ZA 958314 B ZA958314 B ZA 958314B
- Authority
- ZA
- South Africa
- Prior art keywords
- vasation
- ht1f
- migraine
- extra
- treatment
- Prior art date
Links
- 206010015866 Extravasation Diseases 0.000 title 1
- 208000019695 Migraine disease Diseases 0.000 title 1
- 230000036251 extravasation Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
- 230000001272 neurogenic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/318,330 US5698571A (en) | 1994-10-05 | 1994-10-05 | 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA958314B true ZA958314B (en) | 1997-04-03 |
Family
ID=23237717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA958314A ZA958314B (en) | 1994-10-05 | 1995-10-03 | 5-Ht1f mediated inhibition of neurogenic meningeal extra-vasation a method for the treatment of migraine |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5698571A (cs) |
| EP (1) | EP0705600A1 (cs) |
| JP (1) | JPH08208516A (cs) |
| AU (1) | AU688168B2 (cs) |
| CA (1) | CA2159767A1 (cs) |
| CZ (1) | CZ93097A3 (cs) |
| HU (1) | HUT77885A (cs) |
| NO (1) | NO971487D0 (cs) |
| NZ (1) | NZ296252A (cs) |
| RU (1) | RU2183457C2 (cs) |
| TW (1) | TW492864B (cs) |
| UA (1) | UA44284C2 (cs) |
| WO (1) | WO1996011006A1 (cs) |
| ZA (1) | ZA958314B (cs) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406859B1 (en) | 1992-01-08 | 2002-06-18 | Synaptic Pharmaceutical Corporation | DNA encoding a 5-HT 1F receptor and uses thereof |
| DE69610793T2 (de) * | 1995-06-23 | 2001-05-03 | Eli Lilly And Co., Indianapolis | 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US5962473A (en) * | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
| TR199900430T2 (xx) * | 1996-08-28 | 1999-06-21 | Eli Lilly And Company | �kameli 1,2,3,4-tetrahidro-2-dibenzofuranaminler ve 2-aminosiklohepta$b] benzofuranlar. |
| AU4074897A (en) * | 1996-09-18 | 1998-04-14 | Eli Lilly And Company | A method for the prevention of migraine |
| GB9706089D0 (en) * | 1997-03-24 | 1997-05-14 | Scherer Ltd R P | Pharmaceutical composition |
| US6066092A (en) * | 1997-11-06 | 2000-05-23 | Cady; Roger K. | Preemptive prophylaxis of migraine device and method |
| AU4977899A (en) * | 1998-07-27 | 2000-02-21 | Eli Lilly And Company | Treatment of anxiety disorders |
| GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
| US6255334B1 (en) * | 1998-10-30 | 2001-07-03 | Pfizer Inc | 5HT 1 receptor agonists and metoclopramide for the treatment of migraine |
| CA2535082C (en) * | 2000-11-27 | 2013-11-19 | Terry Cassaday | Chair or bed member having data storage |
| US8329734B2 (en) * | 2009-07-27 | 2012-12-11 | Afgin Pharma Llc | Topical therapy for migraine |
| DK1435945T3 (da) * | 2001-06-05 | 2008-12-01 | Ronald Aung-Din | Topisk migræne terapi |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| EP1465869B1 (en) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulators of lxr |
| TWI263497B (en) * | 2002-03-29 | 2006-10-11 | Lilly Co Eli | Pyridinoylpiperidines as 5-HT1F agonists |
| ES2380827T3 (es) * | 2002-12-26 | 2012-05-18 | Pozen, Inc. | Formas de dosificación con múltiples capas que contienen naproxeno y triptanes |
| US20070065463A1 (en) | 2003-06-20 | 2007-03-22 | Ronald Aung-Din | Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| JP2008521771A (ja) | 2004-11-26 | 2008-06-26 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 改良された抗精神病活性および抗不安症活性を有するイソキサゾリン−インドール誘導体 |
| JP2011526889A (ja) | 2008-06-30 | 2011-10-20 | アフギン ファーマ，エルエルシー | 局所局部的神経作用療法 |
| CN102753171A (zh) | 2009-04-02 | 2012-10-24 | 科鲁西德制药公司 | 2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲酰胺的组合物 |
| US8697876B2 (en) | 2010-04-02 | 2014-04-15 | Colucid Pharmaceuticals, Inc. | Compositions and methods of synthesis of pyridinolypiperidine 5-HT1F agonists |
| HK1244715A1 (zh) | 2015-03-02 | 2018-08-17 | 阿福金制药有限责任公司 | 用大麻素的局部区域神经影响性疗法 |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| TWI826514B (zh) * | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| TWI829107B (zh) | 2019-07-09 | 2024-01-11 | 美商美國禮來大藥廠 | 大規模製備2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺半琥珀酸鹽的方法及中間體，以及2,4,6-三氟-n-[6-(1-甲基-哌啶-4-羰基)-吡啶-2-基]-苯甲醯胺醋酸鹽之製備 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL96891A0 (en) * | 1990-01-17 | 1992-03-29 | Merck Sharp & Dohme | Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them |
| US5360735A (en) * | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
-
1994
- 1994-10-05 US US08/318,330 patent/US5698571A/en not_active Expired - Fee Related
-
1995
- 1995-03-10 UA UA97041603A patent/UA44284C2/uk unknown
- 1995-10-03 RU RU97105384/14A patent/RU2183457C2/ru not_active IP Right Cessation
- 1995-10-03 CA CA002159767A patent/CA2159767A1/en not_active Abandoned
- 1995-10-03 EP EP95306998A patent/EP0705600A1/en not_active Withdrawn
- 1995-10-03 TW TW084110318A patent/TW492864B/zh active
- 1995-10-03 ZA ZA958314A patent/ZA958314B/xx unknown
- 1995-10-03 CZ CZ97930A patent/CZ93097A3/cs unknown
- 1995-10-03 JP JP7256141A patent/JPH08208516A/ja active Pending
- 1995-10-03 HU HU9702287A patent/HUT77885A/hu unknown
- 1995-10-03 NZ NZ296252A patent/NZ296252A/en unknown
- 1995-10-03 WO PCT/US1995/013010 patent/WO1996011006A1/en not_active Ceased
- 1995-10-03 AU AU39996/95A patent/AU688168B2/en not_active Ceased
-
1997
- 1997-04-02 NO NO971487A patent/NO971487D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ296252A (en) | 1999-10-28 |
| CZ93097A3 (en) | 1997-09-17 |
| AU3999695A (en) | 1996-05-02 |
| NO971487L (no) | 1997-04-02 |
| AU688168B2 (en) | 1998-03-05 |
| TW492864B (en) | 2002-07-01 |
| HUT77885A (hu) | 1998-09-28 |
| WO1996011006A1 (en) | 1996-04-18 |
| RU2183457C2 (ru) | 2002-06-20 |
| US5698571A (en) | 1997-12-16 |
| NO971487D0 (no) | 1997-04-02 |
| EP0705600A1 (en) | 1996-04-10 |
| CA2159767A1 (en) | 1996-04-06 |
| MX9702478A (es) | 1997-07-31 |
| UA44284C2 (uk) | 2002-02-15 |
| JPH08208516A (ja) | 1996-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA958314B (en) | 5-Ht1f mediated inhibition of neurogenic meningeal extra-vasation a method for the treatment of migraine | |
| ZA959169B (en) | Method for treating anxiety | |
| MX195979B (en) | Process for the polynitration of aromatic compounds | |
| PL328598A1 (en) | Method of inhibiting the occurrence of polymerisation process during distillation of aromatic vinyl compounds | |
| ZA955177B (en) | Process for the direct reduction of iron-oxide-containing material | |
| PL334012A1 (en) | Novel method of treating the arthritis | |
| AU4074897A (en) | A method for the prevention of migraine | |
| HUP0102798A3 (en) | Method for the heat treatment of solids | |
| IL121883A0 (en) | Apparatus and method for the purification of water | |
| GB2292532B (en) | Fluid treatment process | |
| ZA952344B (en) | Novel protease for treating devitalized tissue | |
| HUP0102393A3 (en) | Method and apparatus for the treatment of a melt | |
| HU9503330D0 (en) | Process for treating sewage | |
| EP0749314A4 (en) | PROCESS FOR THE TREATMENT AND INHIBITION OF GASTRIC AND DUODENAL ULCERS | |
| GB9425557D0 (en) | Method for the prevention of cathodic disbondment | |
| EP0769904A4 (en) | METHOD FOR TREATING ANXIETIES | |
| EP0783304A4 (en) | METHOD FOR TREATING FEELINGS | |
| GB9501400D0 (en) | Method for treating water | |
| AU1440597A (en) | Cyanide removal from process water | |
| GB9725895D0 (en) | Process for the removal of contaminants | |
| HU9601826D0 (en) | A method of treating neurogenic inflammation | |
| ZA989940B (en) | Process for the treatment of highly ammonium-loaded process waste water | |
| IL111762A0 (en) | Apparatus for treatment of migraine | |
| GB2279070B (en) | Process for the treatment of sewage | |
| GB9625410D0 (en) | Process for the removal of contaminants |